Risk of Acute Kidney Injury to Patients on Concomitant Tazobactam/piperacillin and Vancomycin Compared to Those on Meropenem and Vancomycin

Abstract

Overseas reports indicate that combination therapy with tazobactam/piperacillin (T/P) and vancomycin (VCM) frequently causes acute kidney injury (AKI). In this study, we retrospectively compared AKI frequency in cases receiving T/P + VCM and those receiving meropenem (MEPM) and VCM, another combination used in our hospital for empiric similar coverage. AKI incidence in the T/P + VCM (Eight of 25 cases; 32.0%) was significantly higher than that in the MEPM + VCM (five of 63 cases; 7.9%). A multivariate analysis identified T/P use as the only independent risk factor for AKI (odds ratio 6.77, 95%CI 1.43-32.09). Kidney function should be monitored carefully when T/P + VCM is used regardless of VCM trough values.